Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

被引：2

作者：

Bhutani, Manisha ^{[1
]}

Robinson, Myra ^{[2
]}

Atrash, Shebli ^{[1
]}

Paul, Barry ^{[1
]}

Pineda-Roman, Mauricio ^{[1
]}

Foureau, David ^{[3
]}

Varga, Cindy ^{[1
]}

Friend, Reed ^{[1
]}

Begic, Xhevahire ^{[4
]}

Norek, Sarah ^{[4
]}

Drennan, Tiffany ^{[5
]}

Anderson, Michelle B. ^{[6
]}

Symanowski, James ^{[2
]}

Voorhees, Peter M. ^{[7
]}

Usmani, Saad Z. ^{[8
]}

机构：

[1] Atrium Hlth, Dept Hematol Oncol & Blood Disorders, Levine Canc Inst, Charlotte, NC USA

[2] Atrium Hlth, Levine Canc Inst, Dept Canc Biostat, Charlotte, NC USA

[3] Atrium Hlth, Levine Canc Inst, Immune Monitoring Core Lab, Charlotte, NC USA

[4] Atrium Hlth, Levine Canc Inst, Sponsored Res Coordinating Ctr, Charlotte, NC USA

[5] Atrium Hlth, Levine Canc Inst, Clin Trials Unit, Charlotte, NC USA

[6] Atrium Hlth, Levine Canc Inst, Biostat & Data Sci, Charlotte, NC USA

[7] Wake Forest Univ, Sch Med, Atrium Hlth, Dept Hematol Oncol & Blood Disorders,Levine Canc, Charlotte, NC USA

[8] Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174972

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[11] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in newly diagnosed Multiple Myeloma (NDMM): analysis of vascular thrombotic events (VTEs) in the GRIFFIN study
Sborov, Douglas
Baljevic, Muhamed
Reeves, Brandi
Laubach, Jacob
Efebera, Yvonne
Rodriguez, Cesar
Costa, Luciano
Chari, Ajai
Silbermann, Rebecca
Holstein, Sarah
Anderson, Larry D., Jr.
Kaufman, Jonathan
Shah, Nina
Pei, Huiling
Patel, Sharmila
Cortoos, Annelore
Bartlett, Blake
Vermeulen, Jessica
Lin, Thomas
Voorhees, Peter
Richardson, Paul G.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S135 - S136
[12] Daratumumab (DARA) plus lenalidomide/bortezomib/dexamethasone (RVd) in Black patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): an updated subgroup analysis of GRIFFIN
Nooka, Ajay
Kaufman, Jonathan
Rodriguez, Cesar
Jakubowiak, Andrzej
Efebera, Yvonne
Reeves, Brandi
Wildes, Tanya
Holstein, Sarah
Anderson, Larry
Badros, Ashraf
Shune, Leyla
Chari, Ajai
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas
Usmani, Saad
Richardson, Paul
Voorhees, Peter
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S155 - S156
[13] A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
Derman, Ben A.
Major, Ajay
Rosenblatt, Jacalyn
Avigan, David
Rampurwala, Murtuza M.
Alcantar, Luis
Libao, Bernadette M.
McIver, Amanda
Andreatos, Evangelia
Major, Sarah
Wolfe, Brittany
Gorski, Martha
Karrison, Theodore G.
Stefka, Andrew
Jakubowiak, Andrzej
BLOOD, 2021, 138
[14] CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE (KRD) WITH OR WITHOUT TRANSPLANTATION IN NEWLY DIAGNOSED MYELOMA PATIENTS: SUBGROUP ANALYSIS IN THE FORTE TRIAL
Gay, F.
Cerrato, C.
Petrucci, M. T.
Zambello, R.
Rivolti, E.
Ballanti, S.
Omede, P.
Gentile, M.
Bernardini, A.
Narni, F.
Capra, A.
De Sabbata, G.
Gozzetti, A.
Galieni, P.
Rizzi, R.
Pescosta, N.
Cea, M.
Molica, S.
Cafro, A.
Musolino, C.
Spadano, A.
Montefusco, V.
Musto, P.
Cavo, M.
Boccadoro, M.
HAEMATOLOGICA, 2019, 104 : 2 - 3
[15] Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma
Kumar, Shaji K.
Kapoor, Prashant
Laplant, Betsy
Muchtar, Eli
Buadi, Francis K.
Gonsalves, Wilson I.
Dingli, David
Go, Ronald S.
Warsame, Rahma
Kourelis, Taxiarchis
Lust, John A.
Lacy, Martha Q.
Dispenzieri, Angela
Hayman, Suzanne R.
Hwa, Yi
Fonder, Amie
Hobbs, Miriam
Leung, Nelson
Rajkumar, S. Vincent
Gertz, Morie A.
Wolfe, Eric
BLOOD, 2018, 132
[16] Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial
Jacobus, Susanna J.
Cohen, Adam D.
Weiss, Matthias
Callander, Natalie Scott
Singh, Avina A.
Parker, Terri L.
Menter, Alex R.
Yang, Xuezhong
Parsons, Benjamin Marshall
Kumar, Pankaj
Kapoor, Prashant
Rosenberg, Aaron Seth
Zonder, Jeffrey A.
Faber, Edward Anthony
Lonial, Sagar
Richardson, Paul G.
Orlowski, Robert Z.
Wagner, Lynne I.
Rajkumar, S. Vincent
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (18)
[17] Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study
Chari, Ajai
Usmani, Saad Z.
Krishnan, Amrita
Lonial, Sagar
Comenzo, Raymond
Wu, Kaida
Wang, Jianping
Doshi, Parul
Weiss, Brendan M.
Schecter, Jordan
Jakubowiak, Andrzej J.
BLOOD, 2017, 130
[18] Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study.
Jakubowiak, Andrzej J.
Chari, Ajai
Lonial, Sagar
Weiss, Brendan M.
Comenzo, Raymond L.
Wu, Kaida
Khokhar, Nushmia Z.
Wang, Jianping
Doshi, Parul
Usmani, Saad Zafar
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[19] Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyeLome (IFM) Krd Phase II Study
Roussel, Murielle
Lauwers-Cances, Valerie
Robillard, Nelly
Belhadj, Karim
Facon, Thierry
Garderet, Laurent
Escoffre, Martine
Pegourie, Brigitte
Benboubker, Lotfi
Caillot, Denis
Fohrer, Cecile
Moreau, Philippe
Leleu, Xavier
Avet-Loiseau, Herve
Attal, Michel
BLOOD, 2016, 128 (22)
[20] Comparative Efficacy of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Vs. Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRD) in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
Wang, Yuqi
Huan, Chen
Hanzhen, Zhang
Zhang, Shanshan
Yuan, Youhai
Feng, Ru
Wei, Yongqiang
Wei, Xiaolei
BLOOD, 2024, 144 : 7031 - 7031

← 1 2 3 4 5 →